Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update
Rhea-AI Summary
Numinus Wellness (OTC Pink: NUMIF) reported Q4 fiscal 2025 revenue of $2.33 million, a 29.0% increase over Q3 2025, with gross profit of $1.42 million and gross margin of 61.2%. CCR revenue declined 13.2% to $1.4 million, while Practitioner Training revenue rose 387.6% to $1.0 million.
Operating expenses and other items increased to $2.88 million, driving a quarterly loss of $0.88 million. Numinus ended the quarter with $0.5 million in cash and a $2.7 million working capital deficiency. The company remains under a cease trade order and is focused on completing outstanding audits and interim filings to seek revocation and advance its planned CSE listing.
Operationally, CCR managed 18 clinical trials and 306 patient appointments in Q4. Practitioner Training achieved $1.2 million profit for the year. Subsequent to quarter-end, a U.S. executive order committed US$50 million to psychedelic treatment programs, which Numinus views as a supportive regulatory development. The company also appointed former CFO John Fong as an independent director and Audit Committee member.
Positive
- Total revenue $2.33M in Q4 2025, up 29.0% QoQ
- Gross profit $1.42M in Q4 2025; margin improved to 61.2%
- Practitioner Training revenue $1.0M in Q4 2025, up 387.6% QoQ
- Practitioner Training full-year result $1.2M profit vs prior-year loss
- CCR activity 18 clinical trials and 306 patient appointments in Q4 2025
- Board strengthening addition of former CFO John Fong as independent director and Audit Committee member
Negative
- Operating expenses and other items $2.88M in Q4 2025, up 71.8% QoQ
- Quarterly loss $0.88M in Q4 2025, larger than Q3 loss
- CCR revenue down 13.2% QoQ to $1.4M due to seasonality
- Cash and equivalents only $0.5M with working capital deficiency of $2.7M
- Cease trade order remains in place pending completion of audit and interim filings
- CSE listing still contingent on meeting exchange requirements and regulatory approvals
News Explained
The announced
AI-generated analysis. How Rhea-AI works. Not financial advice.
Q4 Fiscal 2025 Highlights
- Revenue of
$2.3 million , a29.0% increase over Q3 2025 - Gross profit of
$1.4 million , compared to a gross profit of$0.8 million in Q3 2025 - Cash position of
$0.5 million as of August 31, 2025
Subsequent to Quarter End
- On April 18, 2026, President Donald Trump signed an executive order directing U.S. federal agencies to accelerate research, access, and regulatory review for psychedelic-based treatments, including psilocybin, ibogaine, MDMA, and LSD, and committing US
$50 million in federal support for state-level programs. The Company views this as a meaningful regulatory development for its clinical research operations and practitioner training programs, both of which are actively engaged in psychedelic research delivery and practitioner readiness. The ultimate impact, however, will depend on further agency implementation by the FDA and DEA.
All financial results are reported in Canadian dollars unless otherwise stated.
Vancouver, British Columbia--(Newsfile Corp. - August 28, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and year ended August 31, 2025 ("Q4 2025").
Revenue from continuing operations
The Company's consolidated revenues increased by
Revenues from Cedar Clinical Research ("CCR") operations during Q4 2025 decreased by
Revenues from Practitioner Training during Q4 2025 increased by
Gross Margin
Gross margin in Q4 2025 was
Operating expenditures
Operating expenditures and other items were
Operational Highlights
Numinus Clinical Research
Revenues from CCR during Q4 2025 were
CCR managed 18 clinical trials, including 306 patient appointments in Q4 2025, compared to 15 clinical trials and 233 patient appointments in Q3 2025.
Practitioner Training
Practitioner Training revenue increased by
Practitioner Training reached a milestone profit of
Balance Sheet and Liquidity
Numinus ended the quarter with cash and cash equivalents of
Q4 2025 Performance Metrics
| For the quarter ended: | ||||||
| August 31, 2025 (Q4 2025) | May 31, 2025 (Q3 2025) | % change | ||||
| Total Revenue | ||||||
| Cost of revenue | 902,926 | 932,842 | - | |||
| Gross Profit (Loss) | ||||||
| Gross profit margin (loss) | 2680 bps | |||||
| Operating expenses and other items | 2,882,259 | 1,667,279 | ||||
| Loss and comprehensive loss | ( | ( | n/a | |||
Numinus' consolidated financial statements for the year ended August 31, 2025, and related management's discussion and analysis are available on Numinus' Investor Relations website at www.investors.numinusnetwork.com and under the Company's profile on SEDAR+ at www.sedarplus.ca. These documents were prepared in accordance with IFRS.
Financial Reporting Update
The Company continues to advise that the completion of the August 31, 2025, audit, together with the imminent filing of the Company’s outstanding interim financial reports, is a central component of management’s plan to satisfy the regulatory requirements necessary to have the cease trade order that is currently in place with respect to the Company (the “CTO”) revoked.
Management remains focused on completing the remaining interim financial reports, satisfying all regulatory requirements necessary to have the CTO revoked, and advancing the Company's previously announced application to list its common shares on the Canadian Securities Exchange (the "CSE"). Successfully executing these steps remains management's primary strategy to restore trading, enhance shareholder liquidity, and position the Company for its next phase of growth. A listing on the CSE will be contingent on the Company satisfying the CSE’s listing requirements and being approved for listing on that exchange.
Board Appointment
The Company is pleased to announce the appointment of John Fong, former CFO of Numinus Wellness Inc., as a member of the Company's Board of Directors and the Board's Audit Committee. Following his departure from Numinus, Mr. Fong founded F28 Studio, a fractional CFO practice serving high-growth companies. F28 turns legacy tools and structures into intelligent systems using AI. Mr. Fong is an independent member of the Board of Directors and its Audit Committee, as well as being financially literate (among other reasons, in light of his prior experience as CFO of the Company).
About Numinus
Numinus Wellness Inc. (OTC Pink: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic research and training – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinusnetwork.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
SOURCE Numinus Wellness Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These and other risk factors are outlined in our annual information form dated July 25, 2025, which is available on SEDAR+ at www.sedarplus.ca. These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws.
For more information:
Investor Contact
Craig MacPhail
invest@numinusnetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311976